Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 5 cycles of 400 mg q6w in the consolidation phase) in patients with locoregionally advanced nasopharyngeal carcinoma.

NCT Number	NCT07373990
Lead Sponsor	Sun Yat-sen University
Conditions	Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Enrollment	418 participants
Start Date	2026-01-15
Primary Completion	2028-04-30 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-28